Ruth O’Regan, MD, and Ann H. Partridge, MD, on HER2+ Breast Cancer: Results From the CLEOPATRA Trial
2016 San Antonio Breast Cancer SymposiumRuth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings on the prognostic associations of TILs in metastatic HER2-positive breast cancer (Abstract S1-04).
Related Videos
Samuel Smith, PhD, on Tamoxifen Adherence: Results of the IBIS-1 Study
Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervent...
Eric P. Winer, MD: The McGuire Lecture
Eric P. Winer, MD, of the Dana-Farber Cancer Institute, summarizes his McGuire lecture on the past and future of breast cancer treatment.
Lisa A. Carey, MD, and Ingrid A. Mayer, MD, on Triple-Negative Breast Cancer: Treatment Challenges
Lisa A. Carey, MD, of the University of North Carolina, and Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discuss the current studies on neoadjuvant sy...
Hyo Sook Han, MD, on Metastatic Breast Cancer: Trial Results on Veliparib, Carboplatin, and Paclitaxel
Hyo Sook Han, MD, of Moffitt Cancer Center, discusses phase II study findings on the efficacy and tolerability of veliparib in combination with carboplatin and paclitaxel vs placebo i...
Peter Bach, MD, on The Global Cost of Cancer Care
Peter Bach, MD, of Memorial Sloan Kettering Cancer Center, summarizes his plenary lecture on drug costs and their effect on the affordability of cancer care worldwide (Plenary Lecture...
